ProCE Banner Activity

KEYNOTE-057 Cohort B: Phase II Trial of Pembrolizumab Monotherapy in Patients With High-Risk Papillary NMIBC

Capsule Summary
Conference Coverage

Pembrolizumab showed durable DFS benefit in approximately one third of patients with BCG-unresponsive high-risk papillary NMIBC ineligible for or who declined radical cystectomy.

Released: February 24, 2023

Expiration: February 23, 2024

Begin Activity


Provided by

ProCE Banner


This activity is supported by educational grants from:

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.